Dendreon Presentation

Dendreon Corporation (DNDN): Targeting Cancer, Transforming Lives ™ Anam Ali Jair Campos Bill Halkiadakis

Biotech Industry Analysis ,[object Object],[object Object],[object Object],[object Object],[object Object]

Biotech Industry Biotech Industry Distribution Participants Customers Pricing Marketing & Promotion Regulation Joint Ventures/ Alliances Products R&D and Manufacturing Competitors Markets

Biotech & Pharmaceutical Market (worldwide) Source: IMS World Review 2007

Worldwide Incidence of Prostate Cancer ,[object Object],[object Object],[object Object],[object Object],[object Object],Courtesy of Science Creative Quarterly

Company Overview ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Defining the Business ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Dendreon’s Purpose ,[object Object],[object Object],[object Object]

Key Points of the Firm ,[object Object],[object Object],[object Object],[object Object]

Treatment Cycle for PROVENGE® ,[object Object],[object Object]

Our Potential Customers ,[object Object],[object Object],[object Object]

Porter’s Five Forces ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Firms Problems ,[object Object],[object Object],[object Object]

Recommendations ,[object Object],[object Object],[object Object],[object Object],[object Object]

Biotechnology Industry ,[object Object],[object Object],[object Object],[object Object]

Industry Growth (2004 – 2008)

Industry Projections ,[object Object],[object Object],[object Object],[object Object]

Projected Growth (2009 – 2013)

Evaluation of Industry Trend Growth Results ,[object Object],[object Object],[object Object]

Financial Analysis (Stock Price) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Financial Analysis (Fundamentals) For the last four years Dendreon has been consistently loosing money from $ 86.46 Million in 2005 to $ 70.48 Million in 2008. Revenues 2008 2007 2006 2005 (In Million) Revenue 0.11 100.0% 0.74 100.0% 0.27 100.0% 0.21 100.0% Other Revenue 0 0.0% 0 0.0% 0 0.0% 0 0.0% Total Revenue 0.11 100.00% 0.74 100.00% 0.27 100.00% 0.21 100.00% Income Statement 2008 2007 2006 2005 (In Million) Total operating Revenue 0.11 52.4% 0.74 352.4% 0.27 128.6% 0.21 100.0% Total Costs and Expenses 70.59 81.4% 102.36 118.1% 97.63 112.6% 86.67 100.0% Net Income -70.48 81.5% -101.62 117.5% -97.36 112.6% -86.46 100.0%

Financial Analysis (Conclusion) ,[object Object],[object Object]

Dendreon Presentation

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Dendreon Presentation

Similar to Dendreon Presentation (20)

More from afa4

More from afa4 (9)

Recently uploaded

Recently uploaded (20)

Dendreon Presentation